RedHill Biopharma releases YELIVA for Prostate Cancer

RedHill Biopharma Ltd., an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal (GI) diseases, including gastrointestinal cancers, today announced the publication of an article evaluating the therapeutic potential of ABC294640, the Company's orally-administered first-in-class Sphingosine kinase 2 (SK2) selective inhibitor, in the treatment of Prostate Cancer. The article, authored by scientists from Apogee Biotechnology Corporation ("Apogee") and from the Kimmel Cancer Center at Thomas Jefferson University, will be published in Molecular Cancer Research and is available online on the journal's website. RedHill acquired the rights to YELIVA (ABC294640) in March 2015 from U.S.-based Apogee.
RedHill has also filed a trademark application with the U.S. Patent and Trademark Office (USPTO) for the new brand name YELIVA™ for ABC294640. Subject to USPTO and FDA approval, the new brand name for the potential commercial product will be YELIVA.

According to Dr. Saltz, new cancer drugs “cost too much,” and physicians have a duty to discuss financial toxicity as well as side effects with patients. Historically, patients with health insurance were shielded from the high cost of medical care, but today, patients find themselves increasingly responsible for a larger proportion of their health care costs, in the form of higher premiums, deductibles and copays. “We have to discuss concerns regarding costs and finances. We have to understand and discuss the limitations of insurance. We need to understand their deductibles and copays,” Dr. Saltz said. “We need to be revealing this [financial] toxicity in our academic journals, just as we report on neutropenia, alopecia and nausea.” A 20% copay for a drug that costs $10,000 per month is an insurmountable hurdle for most individuals. On average, a new cancer drug costs roughly $10,000 per month for a single drug, with some costing more than $30,000.
Echoing the sentiment of many clinicians, Dr. Saltz said current drug pricing models are not rational, but simply reflect what the market will bear.
- See more at: http://www.pharmacypracticenews.com/ViewArticle.aspx?d=Policy&d_id=51&i=August+2015&i_id=1213&a_id=33296#sthash.d6Mu2XpZ.dpufRedHill Biopharma Ltd. RDHL, -7.74% (tase:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal (GI) diseases, including gastrointestinal cancers, today announced the publication of an article evaluating the therapeutic potential of ABC294640, the Company's orally-administered first-in-class Sphingosine kinase 2 (SK2) selective inhibitor, in the treatment of prostate cancer. The article, authored by scientists from Apogee Biotechnology Corporation ("Apogee") and from the Kimmel Cancer Center at Thomas Jefferson University, will be published in Molecular Cancer Research and is available online on the journal's website. RedHill acquired the rights to YELIVA™ (ABC294640) in March 2015 from U.S.-based Apogee.
RedHill has also filed a trademark application with the U.S. Patent and Trademark Office (USPTO) for the new brand name YELIVA™ for ABC294640. Subject to USPTO and FDA approval, the new brand name for the potential commercial product will be YELIVA™.

According to Dr. Saltz, new cancer drugs “cost too much,” and physicians have a duty to discuss financial toxicity as well as side effects with patients. Historically, patients with health insurance were shielded from the high cost of medical care, but today, patients find themselves increasingly responsible for a larger proportion of their health care costs, in the form of higher premiums, deductibles and copays. “We have to discuss concerns regarding costs and finances. We have to understand and discuss the limitations of insurance. We need to understand their deductibles and copays,” Dr. Saltz said. “We need to be revealing this [financial] toxicity in our academic journals, just as we report on neutropenia, alopecia and nausea.” A 20% copay for a drug that costs $10,000 per month is an insurmountable hurdle for most individuals. On average, a new cancer drug costs roughly $10,000 per month for a single drug, with some costing more than $30,000.
Echoing the sentiment of many clinicians, Dr. Saltz said current drug pricing models are not rational, but simply reflect what the market will bear.
- See more at: http://www.pharmacypracticenews.com/ViewArticle.aspx?d=Policy&d_id=51&i=August+2015&i_id=1213&a_id=33296#sthash.d6Mu2XpZ.dpuf